CoChat

Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia

Open access
Syu, Jhih-Pu, Chi, Jen-Tsan, Kung, Hsiu-Ni · 2016 · Oncotarget
Cited by 132

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

// Jhih-Pu Syu 1 , Jen-Tsan Chi 2, 3 , Hsiu-Ni Kung 1 1 Department of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taipei, Taiwan 2 Center for Genomic and Computational Biology, Duke University, Durham, NC, USA 3 Department of Molecular Genetics & Microbiology, Duke University, Durham, NC, USA Correspondence to: Hsiu-Ni Kung, e-mail: kunghsiuni@gmail.com Keywords: Nrf2, hypoxia, drug resistance, antioxidant activity, breast tumor Received: September 02, 2015 Accepted: January 29, 2016 Published: February 15, 2016 ABSTRACT Hypoxia leads to reactive oxygen species (ROS) imbalance, which is proposed to associate with drug resistance and oncogenesis. Inhibition of enzymes of antioxidant balancing system in tumor cells was shown to reduce chemoresistance under hypoxia. However, the underlying mechanism remains unknown. The key regulator of antioxidant balancing system is nuclear factor erythroid 2-related factor 2 (NFE2L2, Nrf2). In this study, we showed that hypoxia induced ROS production and increased the Nrf2 activity. Nrf2 activation increased levels of its downstream target antioxidant enzymes, including GCLC and GCLM. The Nrf2-overexpressing also confers chemo-resistant MCF7 cells under normoxia. The in vivo mouse model also demonstrated that the chemical inhibition of Nrf2 can increase cisplatin (CDDP) cytotoxicity. Together, these results showed that Nrf2 serves as a key regulator in chemotherapeutic resistance under hypoxia through ROS-Nrf2-GCLC-GSH pathway. Therefore, targeting Nrf2 can be a potential treatment for hypoxia-induced drug resistance in breast cancer cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7406

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 132

Metadata

Authors
Syu, J.-P., Chi, J.-T., & Kung, H.-N.
Venue
Oncotarget
Published
2016-02-15
Volume
7
Issue
12
Pages
14659-14672
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2276797747
Cited by
132
References
11
FWCI
5.12
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. https://app.cochat.ai/papers/10.18632/oncotarget.7406
The paper
Syu, J.-P., Chi, J.-T., & Kung, H.-N. (2016). Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. Oncotarget. https://doi.org/10.18632/oncotarget.7406

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.